Phibro Animal Health Stock Analysis
| PAHC Stock | USD 54.62 -0.27 -0.49% |
PAHC is currently below model estimate with Market Value of 54.62 and Intrinsic Value of 63.85. For PAHC, the central analytical question is whether the current price accurately reflects intrinsic value. A low earnings multiple combined with leverage that is elevated relative to health care peers creates a risk-reward dynamic for PAHC where debt sustainability is as important as valuation.
PAHC holds a debt-to-equity ratio of 1.79 relative to health care peers. For Phibro Animal, the trajectory of leverage is a forward indicator: improving leverage suggests deleveraging, while worsening ratios flag capital structure stress. Asset vs Debt
Equity vs Debt
Phibro |
Stock Analysis Notes
About 97.0% of PAHC shares are owned by institutional investors. PAHC has Price/Earnings To Growth (PEG) ratio of 1.68. PAHC had its last dividend issued on the 4th of March 2026. Phibro Animal Health's financial profile includes $1.4 billion in Total Assets and $342.8 million in Current Assets.Investor Insights and Alerts
For Phibro Animal Health, investor alerts are designed to highlight developments that deserve a second look before a position in the stock is increased, reduced, or left unchanged. In practice, the value comes from seeing which signals are new, which are persistent, and which are strong enough to justify action.
| Phibro Animal Health appears to be risky and price may revert if volatility continues | |
| On 25th of March 2026 Phibro Animal paid $ 0.12 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: ILMN Stock Up on Q 1 Earnings Revenue Beat, Margins Expand, 26 View Up |
Environmental, Social, and Governance (ESG) Scores
Reviewing Phibro Animal's ESG trend shows whether governance quality and stakeholder risk are improving or declining. Trend direction often matters more than one isolated ESG reading taken out of context.
Market Capitalization
Current market cap data values Phibro Animal Health at $2.22 billion, which keeps the company in the mid-cap bracket across health care companies. Associated fundamentals relevant to market cap include a workforce of about 2,475 people, about 20.62 million shares outstanding, and operating in the Health Care industry.Profitability
A profitability review of Phibro Animal Health connects sales quality and cost control with the ability to produce steady returns across market cycles. This separates genuinely strong businesses from names that appear cheap only because the market expects weak results. PAHC has Profit Margin (PM) of 6.0%. Similarly, it shows Operating Margin (OM) of 15.0%.Technical Drivers
As of the 4th of May, Phibro Animal reflects a market price of 54.62 per share. Current technical metrics show Semi Deviation of 2.25, risk adjusted performance of 0.1559, and Coefficient Of Variation of 638.28. Technical analytics evaluate momentum, liquidity, and volatility relationships. Current statistics are evaluated within a broader sector context.Price Movement Analysis - Bollinger Bands
This analysis covers thirty-eight data points across the selected time horizon. Bollinger Bands frame Phibro Animal price range using a moving average and volatility bands. Movement toward the lower band may indicate short-term downside pressure, while approaches to the upper band can reflect resistance levels or momentum continuation.
Insider Trading Activities
Reviewing insider trades in Phibro Animal Health shows whether management is acting in line with the public story on growth and strategy. It trades on NASDAQ in US. The business currently sits in the Healthcare sector and the Drug Manufacturers—Specialty & Generic industry.
Outstanding Bonds
Phibro Animal Health may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley Jul Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Predictive Daily Indicators
For active positions in Phibro Animal Health, intraday data shows when a move is gaining strength and when it is fading. The key question is whether the signal helps manage exposure in real time, not whether it predicts every tick.
Corporate Filings
13A | 30th of April 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | |
8K | 27th of April 2026 Report filed with the SEC to announce major events that shareholders should know about | |
F4 | 23rd of April 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | |
F4 | 16th of April 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | |
8K | 14th of April 2026 Report filed with the SEC to announce major events that shareholders should know about | |
13A | 7th of April 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | |
F4 | 31st of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | |
13A | 27th of March 2026 An amended filing to the original Schedule 13G |
Forecast Models
Forecast models for Phibro Animal Health use past prices and returns to estimate how the stock may behave under similar conditions. Financial data rarely stays stable for long, so the model is best used as a probability tool, not a price promise.Debt to Cash Allocation
The debt-to-cash mix for Phibro Animal helps explain how management balances flexibility and funding cost through a business cycle.
Total debt stands at approximately $761.55 million with Debt to Equity (D/E) ratio of 1.79. PAHC has a current ratio of 2.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Phibro Animal's use of debt should be considered alongside its cash position and equity base.Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Phibro Animal's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Phibro Animal, which in turn will lower the firm's financial flexibility.Corporate Bonds Issued
Bond maturity for Phibro Animal is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
Stock Analysis Methodology
Phibro Animal analysis highlights where fundamental and technical signals point to strengths or weak spots. Phibro Animal trades at P/E of 11.39, P/B of 6.69. Phibro Animal shows ROE (TTM) of 31.8% and net margin (TTM) of 6.29%.
Phibro Animal Health data is compiled from periodic company reporting and market reference feeds and standardized for comparability.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Be Your Own Money Manager
Investors considering Phibro Animal Health as part of a broader investment plan should test whether the position improves portfolio quality without taking on avoidable risk. A disciplined process can make capital allocation more consistent and less reactive.